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Polo-like kinase 1 (PLK1) plays an important role in the initiation, maintenance, and completion of mitosis. Dysfunction
of PLK1 may promote cancerous transformation and drive its progression. PLK1 overexpression has been found in a
variety of human cancers and was associated with poor prognoses in cancers. Many studies have showed that
inhibition of PLK1 could lead to death of cancer cells by interfering with multiple stages of mitosis. Thus, PLK1 is
expected to be a potential target for cancer therapy. In this article, we examined PLK1’s structural characteristics, its
regulatory roles in cell mitosis, PLK1 expression, and its association with survival prognoses of cancer patients in a
wide variety of cancer types, PLK1 interaction networks, and PLK1 inhibitors under investigation. Finally, we discussed
the key issues in the development of PLK1-targeted cancer therapy.
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Polo-like kinases (PLKs) are a family of serine/threonine protein kinases
which are widespread in eukaryotic cells [1]. Human PLK family
includes five members: PLK1, PLK2, PLK3, PLK4, and PLK5. Among
them, PLK1 was the most investigated [2]. PLK1 plays multiple roles in
the cell cycle: controls mitotic entry and the G2/M checkpoint,
coordinates the centrosome and cell cycles, regulates spindle assembly
and chromosome segregation, exerts multiple functions at the spindle
midzone and during abscission, facilitates DNA replication, and is
involved in cytokinesis and meiosis [3]. PLK1 is essential for precisely
regulating the cell division and maintaining genome stability in mitosis,
spindle assembly, and DNA damage response [2,4]. Previous studies
have shown that PLK1 is highly expressed in most of human cancers,
and its overexpression is associated with poor prognosis in cancer
patients [5–7]. Several reports have shown that blocking the expression
of PLK1 by antibody, RNA interference (RNAi), or kinase inhibitors
can effectively inhibit the proliferation of tumor cells and induce
apoptosis of tumor cells [8,9]. Thus, it has been suggested that PLK1
could be an attractive target for cancer therapy [10]. In this article, we
reviewed PLK1’s functions in cell cycle progression, its roles in human
cancers, and the development of potential inhibitors targeting PLK1 in
cancer treatment.
The Structure Characteristics of PLK1
As the other members in PLK family, PLK1 protein involves a highly
conserved N-terminal kinase catalytic domain (harboring 252 aminoacids), C-terminal polo-box domain (harboring 60-70 amino acids),
and the connecting region in the middle. The N-terminal kinase
domain is a Ser/Thr kinase domain with a T-loop whose
phosphorylation is directly related to the kinase activity of PLK1
[11]. The polo-box domain is a notable feature of PLK family. It is
located in the C-terminal, each of which contains two polo-box
structures, and a flexible structure is in the middle (Figure 1). The
crystal structure of PLK1 shows that the polo-box domain is similar to
two clips, and the phosphopeptide is clamped in the middle [12].
Differing from the other members of PLK family, PLK4 has only one
polo box in the C-terminal polo-box domain [11].
PLK1 protein can bind to phosphopeptide of certain proteins
through the polo-box domain. When it is recruited to a particular cell
position by interacting with different phosphopeptide, its kinase
domain is released. As a result, different proteins or the different sites
of the same protein can be phosphorylated. In a normal condition, the
Figure 1. The domain structure of PLK1. PB1: polo-box 1; PB2: polo-box 2; PBD: polo-box domain.
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Figure 2. The tendency for PLK1 expression in different phases of
mitosis.
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domain to inhibit the phosphorylation of T210 in the kinase, thereby
inhibiting the kinase activity of PLK1. PLK1 is activated when the
polo-box domain binds to its ligand, and separates with the T-loop of
kinase domain [13].
PLK1 and Mitosis
In eukaryotic organisms, cell cycle progression is regulated by
proteolysis and phosphorylation, and the precise regulation is necessary
for the replication of the genetic information in offspring. Any mistakes
in the mitotic or DNA replication process may result in apoptosis or
mutation to form tumors. PLK1 expression is elevated in actively
proliferating cells and is significantly different among different stages of
the cell cycle [14]. The expression of PLK1 is cell cycle dependent,
usually gathers in the centrosome of the spindle poles in early period of
mitosis, and thenmigrates gradually from spindle poles to the equatorial
plate after entering into middle and late period of mitosis. At the end of
mitosis, PLK1 gathers in the midbody. Therefore, PLK1 expression is
barely detectable in G1 and S phase, gradually increases in G2 phase,
and peaks in M phase [14]. After the completion of cell division, PLK1
expression would get a sharp decline and then move into the next loop
of cell cycles (Figure 2).
PLK1 is a key regulator of mitosis initiation. It can drive the
transformation of G2/M phase by controlling the activity of the CDK1/
Cyclin B complex which is necessary for cells' transition from the G2
phase into the M phase [15]. PLK1 regulates cytoplasmic separation and
membrane formation in mitosis telophase via phosphorylating mitotic
kinesin-like protein l [16]. PLK1 also regulates cytokinesis [17]. In late
mitosis, PLK1 protein is gradually inactivated because of the protein
hydrolysis and finally enters into a quiescent state when mitosis ends.PLK1 and Human Cancer
PLK1 Expression in Cancer
Carcinogenesis depends both on the activation of proto-oncogenes
and on the deactivation of tumor suppressor genes [18]. Oncogenes and
tumor suppressor genes are mostly related to cell cycle regulation, and
dysregulation of the cell cycle is the main cause of cancer [19]. Since
PLK1 was found to be highly expressed in primary tumor tissues
more than two decades ago [20], its role as an oncogene has been
identified by many studies [21,22]. A number of studies have revealed
that PLK1 is overexpressed in cancers comparedwith normal controls in
Table 2. Overexpression ofPLK1mRNA and Protein in Human Cancers Reported in Previous Studies
Cancer Type Reference
Lung cancer [32,33]
Breast cancer [30,34–36]
Melanoma [26,37]
Renal cancer [38,39]
Head and neck cancer [25,40,41]
Hepatocellular carcinoma [42–44]
Endometrial carcinoma [45]
Colorectal cancer [6,27,46,47]
Gastric carcinoma [48,49]
Esophageal carcinoma [50,51]
Bladder urothelial carcinoma [52]
Prostate cancer [31]
Cholangiocarcinoma [53]
Glioblastoma [54,55]
Glioma [23,56]
Ovarian cancer [29,57]
Pancreatic cancer [58–60]
Thyroid cancer [24]
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[24], head and neck squamous cell carcinoma [25], melanoma [26],
colorectal cancers [27], esophageal carcinoma [28], ovarian carcinoma
[29], breast cancer [30], and prostate cancer [31].
To examine the expression of PLK1 in various types of human
cancers, we downloaded the RNA-Seq gene expression (Level 3), gene
somatic mutation (Level 2), and clinical data for all of the 33 cancer
types fromTheCancerGenomeAtlas (TCGA) data portal (https://gdc-
portal.nci.nih.gov/). We compared PLK1 expression between cancers
and normal tissue in 19 cancer types (14 cancer types were excluded
from the analysis because of their small numbers or lack of normal
samples) and found that PLK1 has significantly higher expression levels
in cancers than in normal tissue in 18 of the 19 cancer types (Student's
t test, P value b .05) (Table 1). Besides the TCGA data, PLK1 gene and
protein expression has been reported to be elevated in a wide variety of
human cancers compared with normal tissue in a number of previous
studies and to be associated with poor prognoses of cancers (Table 2).
These results confirm that the overexpression of PLK1 gene and protein
is a common feature of human cancers.
PLK1 Expression and Prognosis of Cancer
We compared the overall survival (OS) time between PLK1
higher-expression-level and PLK1 lower-expression-level cancers in 25
cancer types (8 cancer types were excluded from the analysis because of
very few samples having both PLK1 expression and OS data). PLK1
higher-expression-level and lower-expression-level cancer patients were
determined by the median values of PLK1 expression. If the PLK1
expression level in a patient was higher than the median value, the
patient was classified as PLK1 higher expression level; otherwise, patient
was classified as PLK1 lower expression level. Kaplan-Meier survival
curves (Figure 3) show that patients with higher expression levels of
PLK1 have significantly worse OS prognoses than those with lower
expression levels of PLK1 in 10 cancer types: adrenocortical carcinoma
(ACC), BLCA, BRCA, KIRC, KIRP, brain lower-grade glioma (LGG),
LUAD, PAAD, skin cutaneous melanoma (SKCM), andUCEC. In the
other cancer types, both groups of cancer patients show no significant
OS time differences (log-rank test, P value b .05). We also compared
the disease-free survival (DFS) time between PLK1 higher-expression-
level and PLK1 lower-expression-level cancers in 26 cancer types (7
cancer types were excluded from the analysis because of very fewTable 1. Comparison of PLK1 Expression between Cancers and Normal Tissue
Cancer Type Full Name P Value Fold Change *
LUSC Lung squamous cell carcinoma 7.41E-157 20.8
BRCA Breast invasive carcinoma 5.88E-126 11.3
LUAD Lung adenocarcinoma 1.18E-63 9.7
KIRC Kidney renal clear cell carcinoma 2.33E-55 6.1
HNSC Head and neck squamous cell carcinoma 6.52E-50 4.2
LIHC Liver hepatocellular carcinoma 3.59E-40 11.7
UCEC Uterine corpus endometrial carcinoma 1.96E-36 21.3
COAD Colon adenocarcinoma 5.97E-33 2.5
STAD Stomach adenocarcinoma 8.45E-27 4.8
ESCA Esophageal carcinoma 9.52E-27 10.2
BLCA Bladder urothelial carcinoma 4.96E-26 9.1
PRAD Prostate adenocarcinoma 1.29E-22 3.3
KIRP Kidney renal papillary cell carcinoma 6.76E-22 4.7
CHOL Cholangiocarcinoma 6.97E-14 24.3
GBM Glioblastoma multiforme 5.63E-12 12.4
KICH Kidney chromophobe 1.63E-06 3.3
READ Rectum adenocarcinoma 1.06E-05 2.3
PAAD Pancreatic adenocarcinoma 0.04 2.2
* Mean PLK1 expression in cancers/mean PLK1 expression in normal tissue.samples having both PLK1 expression and DFS data). Kaplan-Meier
survival curves (Figure 4) show that patients with higher expression
levels of PLK1 have significantly worse DFS prognoses than those with
lower expression levels of PLK1 in seven cancer types: ACC, KIRC,
KIRP, LGG, LUAD, SKCM, and uveal melanoma (UVM). In the
other cancer types, both groups of cancer patients show no significant
DFS time differences (log-rank test, P value b .05). These results
confirm that overexpression of PLK1 leads to poor clinical outcomes in
cancer [5,7].
Moreover, we compared PLK1 expression levels between early and
late stage of cancer patients in 11 TCGA cancer types which have
relatively complete records of the clinical phenotype. The 11 cancer
types include ACC, BLCA, BRCA, cervical squamous cell carcinoma
and endocervical adenocarcinoma (CESC), CHOL, COAD, lymphoid
neoplasm diffuse large B-cell lymphoma (DLBC), ESCA, GBM,
HNSC, and KICH. We found that PLK1 has significantly higher
expression levels in late stage of cancers than in early stage of cancers in
four cancer types: ACC (Student's t test, P value = 2*10−5, fold change
= 3.3), BRCA (P value = .03, fold change = 1.9), KIRC (P value =
1.7*10−6, fold change = 1.6), and KIRP (P value = .0005, fold change =
1.6). In the other seven cancer types, PLK1 expression levels have no
significant differences between early and late stage of cancers, although
the mean expression levels of PLK1 are higher in late stage of cancers
than in early stage of cancers in six of the seven cancer types (except
COAD). These results indicate that PLK1 upregulation may be
involved in cancer progression and invasion. This is in line with the
results of previous studies [60–62].
Interactions between PLK1 and Other Molecules
PLK1 interacts with a number of gene products (proteins) (Figure 5,
generated by the BioGRID [63]). For example, RSF1 directly binds to
PLK1 to play an important role in PLK1 deposition and function at
mitotic kinetochores [64]; PLK1 phosphorylates PAX3-FOXO1 to
stabilize the protein and has been proposed as a rational target for
treating alveolar rhabdomyosarcoma [65]; CLIP-170 recruits PLK1 to
kinetochores during early mitosis for chromosome alignment [66].
Among the interactive partners with PLK1, tumor suppressor genes are
noteworthy considering the oncogenic role of PLK1 in human cancers.
The tumor suppressor p53 acts as the “guardian of the genome” and
plays an important role in antiproliferation [67]. TP53 mutations and
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Figure 3. Kaplan-Meier survival curves show significant overall survival (OS) time differences between PLK1 higher-expression-level and PLK1 lower-expression-level cancer patients
(log-rank test, P value b .05).
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Figure 4. Kaplan-Meier survival curves show significant disease-free survival (DFS) time differences between PLK1 higher-expression-level and PLK1 lower-expression-level cancer
patients (log-rank test, P value b .05).
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Figure 5. PLK1 interaction networks.
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Previous studies have shown that PLK1 can bind to the
sequence-specific DNA-binding domain of p53 and inhibit the
p53-dependent transcriptional activation as well as proapoptotic activity
by physical interaction and phosphorylation [69]. P53 in turn can
repress expression of PLK1 [70]. By analyses of the TCGA datasets, we
found that PLK1 expression levels are significantly higher in
TP53-mutated cancers than in TP53–wild-type cancers in 17 of the
29 cancer types (4 cancer types were excluded from the analysis because
of their small numbers ofTP53-mutated samples), as shown in Table 3.
These results suggest that p53 may repress PLK1 expression, and once
TP53 mutations result in loss of the p53 transcriptional repression
function, PLK1 would have elevated expression in TP53-mutated
cancers compared with TP53–wild-type cancers.When we focused on the aforementioned 19 cancer types each of
which has a sufficient number of normal control samples, we found
that in 11 of the 19 cancer types, PLK1 expression follows this
pattern: TP53-mutated cancers N TP53–wild-type cancers N normal
controls. The 11 cancer types include BRCA, LUAD, UCEC,
BLCA, LIHC, PRAD, STAD, KIRC, LUSC, KICH, and CHOL
(Figure 6). This pattern indicates that PLK1 has an elevated
expression level in cancers relative to normal tissue and further has an
elevated expression level in TP53-mutated cancers than in TP53–
wild-type cancers, suggesting that the interaction between the
oncogene PLK1 and the tumor suppressor gene TP53 may play an
important role in carcinogenesis.
Some other tumor suppressors such as CHK2 [71], BRCA1/2
[72–75], ATM [76] and ATR [77], BUB1B [78,79], CYLD [80],
Table 3. Comparison of PLK1 Expression between TP53-Mutated and TP53–Wild-Type Cancers
Cancer Type Full Name P Value Fold Change *
BRCA Breast invasive carcinoma 6.45E-52 2.5
LUAD Lung adenocarcinoma 5.14E-23 2.1
UCEC Uterine corpus endometrial carcinoma 1.10E-15 2.2
BLCA Bladder urothelial carcinoma 2.44E-14 1.8
LIHC Liver hepatocellular carcinoma 6.72E-13 2.5
PRAD Prostate adenocarcinoma 1.12E-07 1.8
STAD Stomach adenocarcinoma 1.57E-07 1.5
ACC Adrenocortical carcinoma 2.85E-07 5.4
PAAD Pancreatic adenocarcinoma 6.15E-06 1.7
KIRC Kidney renal clear cell carcinoma 0.0004 2.3
SKCM Skin cutaneous melanoma 0.0004 1.4
SARC Sarcoma 0.001 1.5
LUSC Lung squamous cell carcinoma 0.01 1.3
CESC Cervical squamous cell carcinoma and endocervical
adenocarcinoma
0.02 1.4
KICH Kidney chromophobe 0.03 1.9
DLBC Lymphoid neoplasm diffuse large B-cell Lymphoma 0.03 1.8
CHOL Cholangiocarcinoma 0.05 2.4
* Mean PLK1 expression in TP53-mutated cancers/mean PLK1 expression in TP53–wild-type cancers.
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PLK1. The imbalance between these interactions for regulating
proliferation could be a leading cause of cancer.
In addition to the tumor suppressors, PLK1 interacts with other
classes of genes or proteins such as kinases: AURKA [84,85], BUB1
[86,87], and WEE1 [88]; oncogenes: MDM2 [89] and FOXO3 [90];
and transcriptional factors: HSF1 [91–93], RELA [94], TRIOBP
[95], and FOXM1 [62,96–98], etc. These interactions may be
essential for PLK1 to play an important role in regulation of the cell
cycle, and dysfunction of the interactions could be associated with
cancer and other diseases.
PLK1andTumor Sensitivity toChemotherapy and Radiotherapy
Drug resistance of cancer cells is one of the main reasons for the
failure of chemotherapy in clinic [99,100]. A number of studies have
revealed that targeting PLK1 may be a novel approach for overcoming
drug resistance in cancer chemotherapy. For example, Jimeno et al.
confirmed that PLK1 mediated the resistance to gemcitabine of
pancreatic cancer cells [101]; Tyagi et al. reported that PLK1 silencing
could enhance the sensitivity to cisplatin in human TP53-mutated
epidermal squamous carcinoma cells by upregulating p73a [102];
Gleixner et al. found that BI2536, a small molecule inhibitor of PLK1,
could enhance the inhibition of imatinib and nilotinib on chronic
myeloid leukemia cell growth [103].
In addition, many studies have suggested that PLK1 is potentially
important for radiation sensitizer. For example, Rodel et al. showed
that PLK1 silencing could enhance the sensitivity of rectal cancer to
radiotherapy [47]; Gerster et al. revealed that targeting PLK1
enhanced radiation efficacy for HNSC [40]; Harris et al. found
that using BI2536 before radiotherapy could enhance radiotherapy
sensitivity in medulloblastoma cells [104]. Thus, the inhibition of
PLK1 may overcome drug resistance in cancer chemotherapy and
enhance sensitivity of cancer radiotherapy.
PLK1 as a Target for Cancer Therapy
PLK1 could be a new therapeutic target for cancer because PLK1
knockout can decrease cancer cell survival, induce apoptosis, and increase
the sensitivity to chemotherapy drugs, whereas it has little effect on normal
cells [9,105–107]. A number of studies have shown that inhibiting PLK1expression or function by RNAi or small molecule inhibitors was effective
in control of cancer cell proliferation [38,50,108,109].
RNAi or small interfering RNA (siRNA) technology is used to inhibit
certain gene expression by human intervention. Spänkuch-Schmitt et al.
showed that siRNAs targeting PLK1 reduced cancer cell proliferation,
whereas they had almost no effect on human mammary epithelial cells
[110].McCarroll et al. targeted PLK1 by RNA-interfering nanoparticle-7
that reduced non–small cell lung cancer cell proliferation in a mouse
model [22]. A number of studies have suggested that targeting PLK1 by
siRNA could be a viable approach to cancer therapy [9,60,111].
However, as the synthesis of antisense oligonucleotides is susceptible to
ribozymes' attack and RNAi has security and stability issues, small
molecule inhibitors may be a better option in targeting PLK1 for cancer
therapy than RNAi. PLK1 structure provides two targets: kinase domain
of N-terminal and polo-box domain of C-terminal. Thus, we can divide
PLK1 inhibitors into two classes, ATP-competitive inhibitors and non–
ATP-competitive inhibitors, based on their different action mechanisms
[112] (Table 4).
ATP-competitive inhibitors target the deep groove in the kinase ATP
binding domain [112]. BI2536 is a representative ATP-competitive
inhibitor with strong selective inhibition on PLK1 [103]. It can inhibit
the proliferation of various cancer cell lines fromdifferent tissue sources by
blocking cancer cells in the metaphase of mitosis and leading to apoptosis
[130,131]. Volasertib (BI6727) is another promising PLK1 inhibitor.
Several preclinical experiments have demonstrated that BI6727 is highly
efficacious in inducing tumor regression [116,132–134]. As a result, this
agent has recently been awarded the “Breakthrough Therapy Status” by
the Food and Drug Administration for its significant benefit in treating
acute myeloid leukemia patients [135]. However, because of the high
conservation of ATP binding domains of different kinases and the
frequent mutation in ATP binding sites, cancer patients always develop
resistance to ATP-competitive inhibitors [136]. In addition, the ATP-
competitive inhibitors can often also act on other kinases and therefore are
not specific for PLK1.
In contrast, the polo-box domain is specific to PLKs and therefore
could be a more suitable target for development of selective PLK1
inhibitors. Poloxin, thymoquinone, and purpurogallin are selective
PLK1 inhibitors targeting the polo-box domain of PLK1 [137]. Poloxin
and thymoquinone can block the correct orientation of PLK1, thereby
preventing the mitosis of cancer cells [126]. A recent study showed that
Poloxin-2, an optimized analogue of poloxin, has significantly improved
potency and selectivity over poloxin in inducing mitotic arrest and
apoptosis in cultured human cancer cells [128].
However, so far, the small molecule inhibitors of PLK1 including
BI2536 have not achieved a satisfactory therapeutic effect in clinical
trials [138]. One main reason is the dose-limiting toxicities of PLK1
inhibitors [10]. A recent study revealed that reduced efficacy of the
PLK1 inhibitor BI2536 on progressive hepatocellular carcinoma
was due to low intratumoral drug levels [139].
Concluding Remarks
PLK1 is a key regulator of the cell cycle and an important oncogene in
cancer initiation, progression, and drug resistance. Its overexpression is a
common feature of human cancers (Tables 1 and 2) and is an important
marker for prognosis in cancer (Figures 3 and 4). Inhibition of PLK1
expression could reverse the drug resistance of cancer cells and increase
sensitivity to radiotherapy and chemotherapy. Thus, PLK1 could be a
promising target for cancer treatment. Particularly, Wang and Simon
have proposed that PLK1 is a promising target for treatingTP53-mutated
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Figure 6. PLK1 gene expression level pattern: TP53-mutated cancers N TP53–wild-type cancers N normal controls, in 11 cancer types. TP53+: TP53-mutated cancers; TP53−:
TP53–wild-type cancers.
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Table 4. A List of PLK1 Inhibitors
Inhibitor Status Reference Company or Lab Class
BI2536 Experimental [113] Boehringer Ingelheim ATP-competitive
GSK461364 Experimental [114,115] GlaxoSmithKline ATP-competitive
Volasertib (BI6727) Experimental [115,116] Boehringer Ingelheim ATP-competitive
ZK-thiazolidinone Experimental [115,117] Bayer Schering Pharmacy ATP-competitive
Rigosertib (ON01910) Experimental [118] Onconova Therapeutics Inc. Non–ATP-competitive
Cyclapolin 9 Experimental [119,120] Cyclacel ATP-competitive
GW 843682X Experimental [121] GlaxoSmithKline ATP-competitive
SBE 13 hydrochloride Experimental [122,123] Institute of Organic Chemistry &
Chemical Biology, Goethe-University
ATP-competitive
TAK960 hydrochloride Experimental [124,125] Takeda Pharmaceutical Company ATP-competitive
Poloxin Experimental [126,127] Max Planck Institute of Biochemistry and
Munich Center for Integrated Protein Science
Non–ATP-competitive
Poloxin-2 Experimental [128] Institute of Organic Chemistry, University of Leipzig Non–ATP-competitive
RO3280 Experimental [129] Hoffmann-La Roche ATP-competitive
30 PLK1, A Potential Target for Cancer Therapy Liu et al. Translational Oncology Vol. 10, No. xx, 2016cancers because of its potential synthetic lethality relationship with TP53
[140]. However, to translate the cancer biology of PLK1 into clinical
application, we need to resolve some important issues such as the
following: Is the overexpression of PLK1 in cancer the cause of cancer or
just a consequence of cancer cells' proliferation [141]? What is the key
interactive network of PLK1 underlying the carcinogenesis? What is the
true relationship between p53 and PLK1 in cancer? How can we develop
effective PLK1 inhibitors or improve the clinical efficacy of current PLK1
inhibitors? We believe that the solution to these issues would bring
significant progress in cancer treatment by targeting PLK1 and its related
network or pathway.
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